All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-09-10T18:36:27.000Z

Regulatory Updates

Sep 10, 2019
Share:

Bookmark this article

The beginning of September 2019 has already seen two orphan drug designations (ODD) for drugs designed to treat multiple myeloma (MM).

CT053

On the 2nd September, 2019, the United States (US) Food & Drug Administration (FDA) announced it was granting ODD to CT053. CT053 is a fully human, investigational, anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell product for the treatment of relapsed/refractory MM (RRMM). The FDA had previously awarded Investigational New Drug (IND) clearance to CT053 in June 2019.1,2

This award is based on results from a phase I clinical trial conducted in China. The results of this trial were presented at the 5th Annual Immunotherapy In Myeloma Scientific Workshop in Denver, US. As of the 28th February 2019, 24 patients with R/R MM were treated, with 70.8% of patients achieving a complete response (CR) and 87.5% achieving an overall response. No events of grade ≥3 cytokine release syndrome (CRS) were reported.1,2

Isatuximab

The Korean Ministry of Food and Drug Safety has granted ODD to isatuximab (Isa) for use in combination with pomalidomide (P) and dexamethasone (d, Isa-Pd) in patients who have previously received two or more treatments for R/R MM. This approval is based on the results of the ICARIA-MM trial, presented at the American Society of Clinical Oncology Meeting (ASCO) in June, 2019.3

In the ICARIA-MM phase III study, patients with R/R MM were randomized to either Isa-Pd (n= 154) or Pd alone (n= 153). At a median follow-up of 11.6 months the progression-free survival, as determined by independent review committee assessment, was 11.53 months for patients receiving Isa-Pd compared to 6.47 months for those receiving Pd (P = 0.001). The hazard ratio was 0.596, indicating Isa-Pd significantly improves PFS. Median overall survival was not reached in either arm. The triplet also had a manageable safety profile.4

  1. European Pharmaceutical Review (EPR): Multiple myeloma treatment receives Orphan Drug Designation. https://www.europeanpharmaceuticalreview.com/news/98371/multiple-myeloma-treatment-receives-orphan-drug-designation/ [Accessed 2019 Sep 03]
  2. CARSGEN therapeutics. CARsgen Therapeutics Receives No Objection to Clinical Trial Application from Health Canada for CT053-MM-02, BCMA-CAR-T Cell Therapy for rrMM. http://www.carsgen.com/media/news?id=cascRxXK7e [Accessed 2019 Sep 03]
  3. Korea Biomedical Review. Multiple myeloma treatment isatuximab named orphan drug. http://www.koreabiomed.com/news/articleView.html?idxno=6378 [Accessed 2019 Sep 03]
  4. Richardson P.G. et al. A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Abstract #8004. American Society of Clinical Oncology meeting, Chicago, US. 2019 Jun 02

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox